The stock will trade on the mitapivat PDUFA catalyst (Nov 1, 2026) and the magnitude of the AQVESME launch trajectory. Watch for prescription growth updates and analyst price target revisions following the 68% revenue beat. The cevidoplenib licensing adds pipeline optionality but is early-stage.
Price Chart
Executive Summary
Agios reported Q2 2026 revenue of $44.7M, up 259% YoY and 68% above consensus of $26.7M, driven by the AQVESME launch in thalassemia. EPS of -$1.69 slightly missed consensus of -$1.67. The key catalyst is the FDA Priority Review for mitapivat in sickle cell disease with a PDUFA date of November 1, 2026, which could unlock a major new market.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $44.7M vs consensus $26.7M (68% beat)
- Mitapivat net revenue $44.7M vs $12.5M in Q2 2025 (+259% YoY)
- EPS -$1.69 vs consensus -$1.67 (1.5% miss)
- FDA granted Priority Review for mitapivat sNDA in sickle cell disease, PDUFA Nov 1, 2026
- Cash position $964.8M as of June 30, 2026
- Licensed cevidoplenib for ITP with up to $1.0B peak U.S. sales potential
- Discontinued tebapivat in LR-MDS and sickle cell disease
Financial Impact
Revenue beat consensus by $18.0M (68%), driven by AQVESME launch. Net loss narrowed to $100.7M from $112.0M YoY. Cash burn $199.6M in H1 2026.
Risk Factors
- Mitapivat sNDA for sickle cell disease may not receive FDA approval by Nov 1, 2026
- AQVESME launch may decelerate after initial pent-up demand
- Cevidoplenib Phase 3 not starting until H1 2028, no near-term revenue
- Cash burn rate may accelerate with expanded pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 144 | $36.85 | awaiting T+60 | — | $38.03 (+3.20%) |
Oct 22, 2026 5d ago | 144 | $37.00 | awaiting T+60 | — | $38.03 (+2.78%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | $38.03 (+19.03%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.03 (+16.12%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.03 (+16.12%) |
Jul 7, 2026 16w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $38.03 (−13.59%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $38.03 (−0.03%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $38.03 (+8.35%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $38.03 (+19.52%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $38.03 (+35.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers